About this trial
With the widespread use of digital devices and prolonged screen exposure, digital eye strain (DES), also known as computer vision syndrome, has become a global public health concern. Emerging evidence suggests that the gut-eye axis may play an important role in ocular health, as gut microbiota imbalance is associated with systemic inflammation and oxidative stress. Specific probiotics may help alleviate eye discomfort through modulation of immune responses and enhancement of antioxidant defense mechanisms. This randomized, double-blind, placebo-controlled study aims to evaluate the efficacy of supplementation with specific probiotics, Bifidobacterium longum BL531 and Lactobacillus reuteri LR1349, in improving digital eye strain symptoms in adults.
Eligibility criteria
Qualifiers
Men and women aged 20-65 years
Daily digital screen use >6 hours for at least 1 year
Mild to severe digital eye strain (CVS-Q score ≥ 6)
Mild to moderate dry eye symptoms (OSDI ≥ 13)
Disqualifiers
Amblyopia or strabismus
Severe eye diseases (e.g., glaucoma , cataract , retinal disorders, severe corneal disease)
Ocular surgery within the past 12 months
Chronic systemic diseases (e.g., uncontrolled diabetes, autoimmune disease, severe liver/kidney impairment, cancer)
Trial design
Treatments tested in this trial
- Placebo
- BL531_low dose
- BL531_high dose
- LR1349_low dose
- LR1349_high dose